CYBO
Tokyo · Founded 2018
About CYBO
CYBO applies AI to give cells an increase in intelligence. Their cell-measuring technology is made to identify and comprehend cells. By combining hardware like high-speed imaging with software like artificial intelligence and image processing, they can perform cell analysis. They provide a framework that can be used for the manufacture of medications and food items in addition to the diagnosis and treatment of illnesses. Its cell measurement technology is intended to better understand and distinguish cells. This is the foundational technology that they are proud to offer to the world. Furthermore, they have advanced cell analysis by combining software technologies such as AI and image processing with hardware technologies such as high-speed imaging.
Company Facts
- Founded: 2018
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $3.4M
- Funding stage: Early Stage Venture
- Last round: Series A (Jun 2023)
- Website: https://www.cybo.jp/
Industries & Categories
Biotechnology, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/cybo-81158 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.